Wu Taixiang, Li Youping, Bian Zhaoxiang, Liu Guanjian, Moher David
Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, International Clinical Epidemiology Network (INCLEN), West China Hospital, Sichuan University, Chengdu, PR China.
Trials. 2009 Jul 2;10:46. doi: 10.1186/1745-6215-10-46.
The approximately 1100 medical journals now active in China are publishing a rapidly increasing number of research reports, including many studies identified by their authors as randomized controlled trials. It has been noticed that these reports mostly present positive results, and their quality and authenticity have consequently been called into question. We investigated the adequacy of randomization of clinical trials published in recent years in China to determine how many of them met acceptable standards for allocating participants to treatment groups.
The China National Knowledge Infrastructure electronic database was searched for reports of randomized controlled trials on 20 common diseases published from January 1994 to June 2005. From this sample, a subset of trials that appeared to have used randomization methods was selected. Twenty-one investigators trained in the relevant knowledge, communication skills and quality control issues interviewed the original authors of these trials about the participant randomization methods and related quality-control features of their trials.
From an initial sample of 37,313 articles identified in the China National Knowledge Infrastructure database, we found 3137 apparent randomized controlled trials. Of these, 1452 were studies of conventional medicine (published in 411 journals) and 1685 were studies of traditional Chinese medicine (published in 352 journals). Interviews with the authors of 2235 of these reports revealed that only 207 studies adhered to accepted methodology for randomization and could on those grounds be deemed authentic randomized controlled trials (6.8%, 95% confidence interval 5.9-7.7). There was no statistically significant difference in the rate of authenticity between randomized controlled trials of traditional interventions and those of conventional interventions. Randomized controlled trials conducted at hospitals affiliated to medical universities were more likely to be authentic than trials conducted at level 3 and level 2 hospitals (relative risk 1.58, 95% confidence interval 1.18-2.13, and relative risk 14.42, 95% confidence interval 9.40-22.10, respectively). The likelihood of authenticity was higher in level 3 hospitals than in level 2 hospitals (relative risk 9.32, 95% confidence interval 5.83-14.89). All randomized controlled trials of pre-market drug clinical trial were authentic by our criteria. Of the trials conducted at university-affiliated hospitals, 56.3% were authentic (95% confidence interval 32.0-81.0).
Most reports of randomized controlled trials published in some Chinese journals lacked an adequate description of randomization. Similarly, most so called 'randomized controlled trials' were not real randomized controlled trials owing to a lack of adequate understanding on the part of the authors of rigorous clinical trial design. All randomized controlled trials of pre-market drug clinical trial included in this research were authentic. Randomized controlled trials conducted by authors in high level hospitals, especially in hospitals affiliated to medical universities had a higher rate of authenticity. That so many non-randomized controlled trials were published as randomized controlled trials reflected the fact that peer review needs to be improved and a good practice guide for peer review including how to identify the authenticity of the study urgently needs to be developed.
目前中国约有1100种医学期刊,发表的研究报告数量迅速增加,其中许多研究被作者认定为随机对照试验。人们注意到,这些报告大多呈现阳性结果,其质量和真实性因此受到质疑。我们调查了近年来中国发表的临床试验随机化的充分性,以确定其中有多少符合将参与者分配到治疗组的可接受标准。
在中国知网电子数据库中搜索1994年1月至2005年6月发表的关于20种常见疾病的随机对照试验报告。从这个样本中,选择了一组似乎使用了随机化方法的试验。21名接受过相关知识、沟通技巧和质量控制问题培训的研究人员就这些试验的参与者随机化方法及其试验的相关质量控制特征采访了这些试验的原始作者。
在中国知网数据库中最初识别出的37313篇文章样本中,我们发现了3137项明显的随机对照试验。其中,1452项是关于传统医学的研究(发表在411种期刊上),1685项是关于中医药的研究(发表在352种期刊上)。对这些报告中的2235篇的作者进行的访谈显示,只有207项研究遵循了公认的随机化方法,因此可以被视为真正的随机对照试验(6.8%,95%置信区间5.9 - 7.7)。传统干预措施的随机对照试验与传统干预措施的随机对照试验之间的真实性率没有统计学上的显著差异。在医科大学附属医院进行的随机对照试验比在二级和三级医院进行的试验更有可能是真实的(相对风险分别为1.58,95%置信区间1.18 - 2.13,以及相对风险14.42,95%置信区间9.40 - 22.10)。三级医院的真实性可能性高于二级医院(相对风险9.32,95%置信区间5.83 - 14.89)。根据我们的标准,所有上市前药物临床试验的随机对照试验都是真实的。在大学附属医院进行的试验中,56.3%是真实的(95%置信区间32.0 - 81.0)。
一些中文期刊发表的随机对照试验报告大多缺乏对随机化的充分描述。同样,由于作者对严格的临床试验设计缺乏充分理解,大多数所谓的“随机对照试验”并非真正的随机对照试验。本研究中纳入的所有上市前药物临床试验的随机对照试验都是真实的。作者在高水平医院,特别是医科大学附属医院进行的随机对照试验真实性率较高。如此多的非随机对照试验被当作随机对照试验发表,这反映出同行评审需要改进,迫切需要制定一份包括如何识别研究真实性的同行评审良好实践指南。